Liberia may only have five Ebola patients left, but GSK is still planning to carry out a huge clinical phase 3 trial of its experimental Ebola vaccine after skipping clinical phase 2 trials altogether.
While GSK and its partners have started recruiting the first participants to take their experimental jab, they do not seem to be giving Liberians information about the risks of their vaccine, something required under the terms of informed consent.
Informed consent by participants in the clinical trial was made a pre condition of Ebola vaccine trials by WHO ethics experts at a meeting on August 11th, 2014, as reported by The Guardian.
“There must be complete transparency about the implications of the treatment and patients and their families must give informed consent – which means they must understand the risks as well as the possible benefits. There must also be freedom of choice, confidentiality, respect for…
View original post 142 more words